Salud financiera de hoja de balance de JHS Svendgaard Laboratories

Salud financiera controles de criterios 4/6

JHS Svendgaard Laboratories tiene un patrimonio de los accionistas total de ₹1.7B y una deuda total de ₹35.6M, lo que sitúa su ratio deuda-patrimonio en 2.1%. Sus activos y pasivos totales son ₹2.0B y ₹259.0M respectivamente.

Información clave

2.1%

Ratio deuda-patrimonio

₹35.63m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	₹72.29m
Patrimonio	₹1.71b
Total pasivo	₹258.97m
Activos totales	₹1.97b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

JHS Svendgaard Laboratories Limited (NSE:JHS) Not Doing Enough For Some Investors As Its Shares Slump 33%

Mar 07

JHS Svendgaard Laboratories Limited's (NSE:JHS) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Jan 22

A Look At The Fair Value Of JHS Svendgaard Laboratories Limited (NSE:JHS)

Aug 19

There Are Reasons To Feel Uneasy About JHS Svendgaard Laboratories' (NSE:JHS) Returns On Capital

Aug 04

JHS Svendgaard Laboratories (NSE:JHS) Will Want To Turn Around Its Return Trends

Apr 09

Estimating The Fair Value Of JHS Svendgaard Laboratories Limited (NSE:JHS)

Dec 01

Here’s What’s Happening With Returns At JHS Svendgaard Laboratories (NSE:JHS)

Jun 25

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (₹826.2M) de JHS superan a sus pasivos a corto plazo (₹216.5M).

Pasivo a largo plazo: Los activos a corto plazo de JHS (₹826.2M) superan a sus pasivos a largo plazo (₹42.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: JHS tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de JHS ha pasado de 3.2% a 2.1% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: JHS tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: JHS tiene menos de un año de cash runway si el flujo de caja libre sigue creciendo a tasas históricas de 5.7% cada año.

Salud financiera de hoja de balance de JHS Svendgaard Laboratories

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

JHS Svendgaard Laboratories Limited (NSE:JHS) Not Doing Enough For Some Investors As Its Shares Slump 33%

Third quarter 2024 earnings released: EPS: ₹0.002 (vs ₹0.24 loss in 3Q 2023)

JHS Svendgaard Laboratories Limited to Report Nine Months, 2024 Results on Feb 14, 2024

New major risk - Share price stability

JHS Svendgaard Laboratories Limited's (NSE:JHS) Price Is Right But Growth Is Lacking After Shares Rocket 27%

New minor risk - Share price stability

Second quarter 2024 earnings released: ₹0.09 loss per share (vs ₹0.03 loss in 2Q 2023)

JHS Svendgaard Laboratories Limited to Report First Half, 2024 Results on Nov 07, 2023

JHS Svendgaard Laboratories Limited Announces the Resignation of Mr. Deepesh Sharma as Joint Chief Financial Officer

JHS Svendgaard Laboratories Limited Announces Cessation of Rohina Sanjay Sangtani as Independent Director

New minor risk - Shareholder dilution

JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 28, 2023

JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 28, 2023

A Look At The Fair Value Of JHS Svendgaard Laboratories Limited (NSE:JHS)

JHS Svendgaard Laboratories Limited (NSEI:JHS) agreed to acquire Vedic Cosmeceuticals Pvt. Ltd.

First quarter 2024 earnings released: ₹0.40 loss per share (vs ₹0.59 loss in 1Q 2023)

JHS Svendgaard Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023

New minor risk - Share price stability

Full year 2023 earnings released: ₹2.34 loss per share (vs ₹0.63 loss in FY 2022)

JHS Svendgaard Laboratories Limited Appoints Deepesh Sharma as Joint Chief Financial Officer

JHS Svendgaard Laboratories Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: ₹0.24 loss per share (vs ₹0.04 profit in 3Q 2022)

JHS Svendgaard Laboratories Limited Announces the Resignation of Neeraj Kumar as Joint Chief Financial Officer, Effective March 15, 2023

JHS Svendgaard Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: ₹0.03 loss per share (vs ₹0.05 profit in 2Q 2022)

Second quarter 2023 earnings released: ₹0.03 loss per share (vs ₹0.05 profit in 2Q 2022)

JHS Svendgaard Laboratories Limited Appoints Komal Jha as Company Secretary & Compliance Officer

JHS Svendgaard Laboratories Limited to Report Q2, 2023 Results on Nov 10, 2022

JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 27, 2022

First quarter 2023 earnings released

JHS Svendgaard Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

There Are Reasons To Feel Uneasy About JHS Svendgaard Laboratories' (NSE:JHS) Returns On Capital

Full year 2022 earnings: EPS and revenues exceed analyst expectations

JHS Svendgaard Laboratories Limited Announces Management Changes

Investor sentiment improved over the past week

JHS Svendgaard Laboratories Limited to Report Q4, 2022 Results on May 24, 2022

Investor sentiment improved over the past week

JHS Svendgaard Laboratories (NSE:JHS) Will Want To Turn Around Its Return Trends

Investor sentiment improved over the past week

JHS Svendgaard Laboratories Limited Announces Resignation of Mr. Nokhil Kishorchandra Vora as Nominee Director

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

JHS Svendgaard Laboratories Limited to Report Q3, 2022 Results on Feb 08, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹0.05 (vs ₹0.16 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹0.20 (vs ₹0.33 loss in FY 2020)

JHS Svendgaard Laboratories Limited Update on Its Operations

Third quarter 2021 earnings released: EPS ₹0.02 (vs ₹0.11 in 3Q 2020)

JHS Svendgaard Laboratories Limited to Report Q3, 2021 Results on Feb 09, 2021

New 90-day high: ₹26.90

New 90-day high: ₹26.60

Estimating The Fair Value Of JHS Svendgaard Laboratories Limited (NSE:JHS)

JHS Svendgaard Laboratories Limited to Report Q2, 2021 Results on Nov 03, 2020

First quarter earnings released

JHS Svendgaard Laboratories Limited Announces Resignation of Balbir Verma, Non-Executive Independent Director

JHS Svendgaard Laboratories Limited to Report Q1, 2021 Results on Sep 15, 2020

New 90-day high - ₹19.45

JHS Svendgaard Laboratories Limited announced that it expects to receive INR 27.5 million in funding

Here’s What’s Happening With Returns At JHS Svendgaard Laboratories (NSE:JHS)

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera